[EN] COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE<br/>[FR] COMPOSES, PROCEDES ET PREPARATIONS DESTINES A L'APPORT ORAL D'UN COMPOSE PEPTIDIQUE DE TYPE GLUCAGON (GLP-1) OU D'UN PEPTIDE AGONISTE DU RECEPTEUR 4 DE MELANOCORTINE (MC4)
申请人:LILLY CO ELI
公开号:WO2005019184A1
公开(公告)日:2005-03-03
The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
本发明涉及用于口服给荷GLP-1化合物或MC4激动剂肽的新化合物、方法和配方。
Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
申请人:Herr Robert Jason
公开号:US20080214448A1
公开(公告)日:2008-09-04
The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
本发明涉及一种新型化合物、方法和配方,用于口服给药GLP-1化合物或MC4激动剂肽。
Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands
申请人:Fukumoto Shoji
公开号:US20090253687A1
公开(公告)日:2009-10-08
The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof, or a salt thereof; and an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like.
COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE
申请人:HERR Robert Jason
公开号:US20100120876A1
公开(公告)日:2010-05-13
The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
本发明涉及一种新型化合物、方法和配方,用于口服给药GLP-1化合物或MC4激动剂肽。
Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide
申请人:Herr Robert Jason
公开号:US08552039B2
公开(公告)日:2013-10-08
The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.